Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Findings from the Vax-On study show a favourable safety profile of mRNA-based COVID-19 vaccine in patients with solid tumours during active anticancer treatment
Evidence for efficacy is based on the results from the innovaTV 204 study
Findings from the PANAMA study (AIO KRK 0212)
Findings from the COSMIC-021 study
Findings from a population-based cohort study
The results of the KEYNOTE-122 study
Critical role of government-sponsored cancer research
Findings from samples of the AIO ColoPredictPlus 2.0 registry study
PI3K inhibitor, copanlisib investigated in a phase III, CHRONOS-3 study
Approval is based on the results from the BGB-3111-214 and BGB-3111-AU-003 studies
Findings from a phase II open-label study in patients with localised solid tumours
Development of novel model for prediction of distant relapse in patients with early breast cancer
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
